Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelet activation status decreases after menopause.

José M Aldrighi1, Rute Loreto S Oliveira, Elbio D'Amico

  • 1Heart Institute (InCor), University of São Paulo Medical School, Rua Afonso de Oliveira Santos 50, 3o andar, CEP 05663-030 São Paulo, SP, Brazil. jmaldri@usp.br

Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology
|July 16, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

iCARDIO Alliance global implementation guidelines for the management of obesity 2025 focus on prevention and treatment of cardiometabolic disease.

American journal of preventive cardiology·2026
Same author

CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum.

Cardiovascular diabetology·2026
Same author

Heart failure with reduced ejection fraction in Sweden: patient adherence and persistence to quadruple pharmacotherapy prescription.

European heart journal·2026
Same author

Magnitude of and outcome associated with inappropriate prescribing in heart failure with reduced ejection fraction: an analysis of 50 348 patients from the Swedish Heart Failure Registry.

European journal of heart failure·2026
Same author

iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025.

Journal of cachexia, sarcopenia and muscle·2026
Same author

Pharmacologic pitfalls in heart failure: A guide to drugs that may cause or exacerbate heart failure. A European Journal of Heart Failure expert consensus document.

European journal of heart failure·2025

Menopause is associated with reduced platelet activation, indicated by lower P-selectin and GPIIb-IIIa expression. This finding suggests potential changes in cardiovascular disease risk factors during the climacterium.

Area of Science:

  • Endocrinology and Metabolism
  • Cardiovascular Physiology
  • Hematology

Background:

  • Platelet activation is a known risk factor for cardiovascular disease.
  • Sex hormones, particularly estradiol, are suspected to influence platelet function, with lower levels in menopausal women potentially impacting cardiovascular health.

Purpose of the Study:

  • To investigate the impact of the climacterium, specifically the transition before and after menopause, on platelet activation markers.
  • To compare platelet activation status in premenopausal women versus postmenopausal women.

Main Methods:

  • A cross-sectional study compared 37 female patients: 10 premenopausal (Group A) and 27 postmenopausal (Group B).
  • Platelet activation markers P-selectin and glycoprotein IIb-IIIa complex (GPIIb-IIIa) were measured using flow cytometry.

Related Experiment Videos

  • Plasma thromboxane B2 levels were quantified via enzyme immunoassay.

    • Main Results:

    • Postmenopausal women (Group B) exhibited significantly lower P-selectin binding indices (6.2 +/- 2.9) compared to premenopausal women (Group A: 12.3 +/- 3; p < 0.001).
    • GPIIb-IIIa binding indices were also significantly lower in postmenopausal women (Group B: 16.2 +/- 3.1) versus premenopausal women (Group A: 18.8 +/- 2.3; p < 0.0018).
    • Plasma thromboxane B2 levels did not differ significantly between the groups (p = 0.85).

    Conclusions:

    • The climacterium and associated low estradiol status correlate with decreased platelet activation in women.
    • Further research with larger sample sizes is warranted to establish definitive conclusions regarding cardiovascular disease implications.